SummaryEligible patients will be randomised to receive magrolimab or a magrolimab-placebo, with 75mg/m^2 azacitidine administered on Days 1 to 7 (or Days 1 to 5 and 8 to 9) of each cycle. Magrolimab will be administered via the following dosing regimens - Cycle 1: 1mg/kg priming dose on Days 1 and 4; 15 mg/kg on Day 8; and 30 mg/kg on Days 11, 15, and 22.
Cycle 2: weekly doses of 30 mg/kg on Days 1, 8, 15, and 22.
Cycle 3 and onward: 30 mg/kg every 2 weeks on Days 1 and 15.
Use the hyperlinks, where available to access additional clinical trial information.
Gilead Sciences, Inc.
A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination With Azacitidine Versus Azacitidine Plus Placebo in Treatment-naÃƒÂ¯ve Patients With Higher Risk Myelodysplastic Syndrome